Pharmacological Treatment with Galectin-1 Protects Against Renal Ischaemia-reperfusion Injury

Overview

Journal Sci Rep

Specialty Science

Date 2018 Jun 24

PMID 29934646

Citations 9

Authors

Carla P Carlos

Analice A Silva

Cristiane D Gil

Sonia M Oliani

Affiliations

Soon will be listed here.

Abstract

Galectin-1 protein (GAL-1) has important anti-inflammatory properties, but related pharmacologic approaches to effectively treat or prevent renal ischaemia and reperfusion injury are highly limited. Here, we investigated the effect of GAL-1 in a renal ischaemia-reperfusion injury rat model and an in vitro hypoxia-reoxygenation model with a proximal renal tubular epithelial cell line. In vivo, pretreatment with GAL-1 attenuated the renal parameters changed by ischaemia-reperfusion/hypoxia-reoxygenation, with recovery of renal function, protecting against influx of leukocytes, cell death and oxidative stress. Ischaemia-reperfusion/hypoxia-reoxygenation was also associated with increased renal endogenous expression of GAL-1 and intercellular adhesion molecule 1 (ICAM-1) plus augmented levels of proinflammatory cytokines IL-1β, TNF-α and MCP-1 and decreased anti-inflammatory IL-10 in urine, all of which were abrogated by GAL-1 treatment. In vitro studies demonstrated renal tubular epithelial cells as an important source of GAL-1 during hypoxia-reoxygenation and confirmed the protective effects of exogenous GAL-1 through downregulation of proinflammatory cytokine release by proximal renal tubular epithelial cells. Collectively, our findings confirm the important anti-inflammatory role of GAL-1 in kidney ischaemia and reperfusion injury and indicate its promising use as a therapeutic approach.

Citing Articles

Neuroprotective effects of galectin‑1 on cerebral ischemia/reperfusion injury by regulating oxidative stress.

Zhao J, Zhu R, He F, Wu M, Wu Y, Meng X Exp Ther Med. 2024; 27(4):154.

PMID: 38476925 PMC: 10928996. DOI: 10.3892/etm.2024.12442.

A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis.

Charalampous C, Dasari S, McPhail E, Theis J, Vrana J, Dispenzieri A Kidney Int. 2023; 105(3):484-495.

PMID: 38096952 PMC: 10922603. DOI: 10.1016/j.kint.2023.11.023.

Galectin functions in cancer-associated inflammation and thrombosis.

Kruk L, Braun A, Cosset E, Gudermann T, Mammadova-Bach E Front Cardiovasc Med. 2023; 10:1052959.

PMID: 36873388 PMC: 9981828. DOI: 10.3389/fcvm.2023.1052959.

Galectin-1 in Obesity and Type 2 Diabetes.

Fryk E, Silva V, Jansson P Metabolites. 2022; 12(10).

PMID: 36295832 PMC: 9606923. DOI: 10.3390/metabo12100930.

Galectins-Potential Therapeutic Targets for Neurodegenerative Disorders.

Chaudhary S, Chaudhary S, Rawat S, Kulkarni A, Bilgrami A, Perveen A Int J Mol Sci. 2022; 23(19).

PMID: 36232314 PMC: 9569834. DOI: 10.3390/ijms231911012.

References

Araujo L, Truzzi R, Mendes G, Luz M, Burdmann E, Oliani S . Annexin A1 protein attenuates cyclosporine-induced renal hemodynamics changes and macrophage infiltration in rats. Inflamm Res. 2011; 61(3):189-96. DOI: 10.1007/s00011-011-0400-z. View

Vansthertem D, Cludts S, Nonclercq D, Gossiaux A, Saussez S, Legrand A . Immunohistochemical localization of galectins-1 and -3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat. Histol Histopathol. 2010; 25(11):1417-29. DOI: 10.14670/HH-25.1417. View

Carlos C, Mendes G, Miquelin A, Luz M, da Silva C, van Rooijen N . Macrophage depletion attenuates chronic cyclosporine A nephrotoxicity. Transplantation. 2010; 89(11):1362-70. DOI: 10.1097/tp.0b013e3181da0587. View

Rowshani A, Vereyken E . The role of macrophage lineage cells in kidney graft rejection and survival. Transplantation. 2012; 94(4):309-18. DOI: 10.1097/TP.0b013e318250c10f. View

Shimizu M, Khoshnoodi J, Akimoto Y, Kawakami H, Hirano H, Higashihara E . Expression of galectin-1, a new component of slit diaphragm, is altered in minimal change nephrotic syndrome. Lab Invest. 2008; 89(2):178-95. DOI: 10.1038/labinvest.2008.125. View

Ostalska-Nowicka D, Zachwieja J, Nowicki M, Kaczmarek E, Siwinska A, Witt M . Immunohistochemical detection of galectin-1 in renal biopsy specimens of children and its possible role in proteinuric glomerulopathies. Histopathology. 2007; 51(4):468-76. DOI: 10.1111/j.1365-2559.2007.02818.x. View

Carlos C, Sonehara N, Oliani S, Burdmann E . Predictive usefulness of urinary biomarkers for the identification of cyclosporine A-induced nephrotoxicity in a rat model. PLoS One. 2014; 9(7):e103660. PMC: 4114979. DOI: 10.1371/journal.pone.0103660. View

Rabinovich G, Ariel A, Hershkoviz R, Hirabayashi J, Kasai K, Lider O . Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology. 1999; 97(1):100-6. PMC: 2326819. DOI: 10.1046/j.1365-2567.1999.00746.x. View

Vaidya V, Ozer J, Dieterle F, Collings F, Ramirez V, Troth S . Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010; 28(5):478-85. PMC: 2885849. DOI: 10.1038/nbt.1623. View

10.

Navarro-Antolin J, Redondo-Horcajo M, Zaragoza C, Alvarez-Barrientos A, Fernandez A, Leon-Gomez E . Role of peroxynitrite in endothelial damage mediated by Cyclosporine A. Free Radic Biol Med. 2007; 42(3):394-403. DOI: 10.1016/j.freeradbiomed.2006.11.008. View

11.

Mason S, Lai X, Ringham H, Bacallao R, Harris P, Witzmann F . Differential expression of renal proteins in a rodent model of Meckel syndrome. Nephron Exp Nephrol. 2010; 117(2):e31-8. PMC: 3214820. DOI: 10.1159/000319722. View

12.

Facio Jr F, Sena A, Araujo L, Mendes G, Castro I, Luz M . Annexin 1 mimetic peptide protects against renal ischemia/reperfusion injury in rats. J Mol Med (Berl). 2010; 89(1):51-63. DOI: 10.1007/s00109-010-0684-4. View

13.

Rostoker R, Yaseen H, Schif-Zuck S, Lichtenstein R, Rabinovich G, Ariel A . Galectin-1 induces 12/15-lipoxygenase expression in murine macrophages and favors their conversion toward a pro-resolving phenotype. Prostaglandins Other Lipid Mediat. 2013; 107:85-94. DOI: 10.1016/j.prostaglandins.2013.08.001. View

14.

Han W, Bailly V, Abichandani R, Thadhani R, Bonventre J . Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002; 62(1):237-44. DOI: 10.1046/j.1523-1755.2002.00433.x. View

15.

Cooper D, Iqbal A, Gittens B, Cervone C, Perretti M . The effect of galectins on leukocyte trafficking in inflammation: sweet or sour?. Ann N Y Acad Sci. 2012; 1253:181-92. DOI: 10.1111/j.1749-6632.2011.06291.x. View

16.

Cooper D, Norling L, Perretti M . Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J Leukoc Biol. 2008; 83(6):1459-66. DOI: 10.1189/jlb.1207831. View

17.

Burger A, Filsinger S, Cooper D, Hansch G . Expression of the 14 kDa galactose-binding protein, galectin-1, on human tubular epithelial cells. Kidney Int. 1996; 50(3):754-9. DOI: 10.1038/ki.1996.373. View

18.

Gil C, Cooper D, Rosignoli G, Perretti M, Oliani S . Inflammation-induced modulation of cellular galectin-1 and -3 expression in a model of rat peritonitis. Inflamm Res. 2006; 55(3):99-107. DOI: 10.1007/s00011-005-0059-4. View

19.

Kathiriya J, Nakra N, Nixon J, Patel P, Vaghasiya V, AlHassani A . Galectin-1 inhibition attenuates profibrotic signaling in hypoxia-induced pulmonary fibrosis. Cell Death Discov. 2017; 3:17010. PMC: 5385413. DOI: 10.1038/cddiscovery.2017.10. View

20.

Norling L, Sampaio A, Cooper D, Perretti M . Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking. FASEB J. 2007; 22(3):682-90. DOI: 10.1096/fj.07-9268com. View